The focus of cardiovascular disease prevention has shifted from normalisation of risk factors to absolute risk reduction. Reducing LDL cholesterol concentration by 1 mmol/L for about 5 years is consistently associated with a 23–25% lowered risk of major cardiovascular events, with statin and non-statin therapies alike, irrespective of baseline LDL cholesterol concentration.¹ In high-income and middle-income countries, statins are now routinely recommended as first-line LDL cholesterol-lowering therapy for people with 10-year modelled risk above, somewhat arbitrary, country-specific thresholds defined by economic and clinical considerations.

中文翻译：

---

PCSK9抑制与2型糖尿病

预防心血管疾病的重点已从风险因素的正常化转向绝对风险的降低。将LDL胆固醇浓度降低1 mmol / L约5年，无论他汀类药物和非他汀类药物的治疗方法如何，无论基线LDL胆固醇浓度如何，其主要心血管事件的发生风险均降低23–25％。¹在高收入和中等收入国家，现在常规推荐使用他汀类药物作为一线LDL降低胆固醇的治疗方法，用于具有10年模拟风险的人群，该风险高于经济和临床考虑所定义的某些特定国家阈值。